Dronabinol - Michael James Enterprises
Latest Information Update: 23 Sep 2016
At a glance
- Originator RP Capital Group
- Developer Michael James Enterprises; University of Illinois at Chicago
- Class Antiemetics; Appetite stimulants; Cannabinoids; Muscle relaxants; Non-opioid analgesics; Small molecules
- Mechanism of Action Cannabinoid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Sleep apnoea syndrome